A Guide To The Risks Of Investing In Taysha Gene Therapies Inc. (TSHA)

ZOM Stock
ZOM Stock

In a filing, Taysha Gene Therapies Inc. revealed its Chief Financial Officer Alam Kamran unloaded Company’s shares for reported $76890.0 on Aug 24. In the deal valued at $2.33 per share,33,000 shares were sold. As a result of this transaction, Alam Kamran now holds 258,042 shares worth roughly $ 0.94 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Manning Paul B bought 16,466,667 shares, generating $14,820,000 in total proceeds. Upon buying the shares at $0.90, the 10% Owner now owns 16,466,667 shares.

Before that, Nolan Sean P. bought 444,444 shares. Taysha Gene Therapies Inc. shares valued at $400,000 were divested by the Chief Executive Officer at a price of $0.90 per share. As a result of the transaction, Nolan Sean P. now holds 1,535,545 shares, worth roughly $5.57 million.

Jefferies downgraded its Taysha Gene Therapies Inc. [TSHA] rating to a Hold from a a Buy in a research note published on Friday, February 01, 2023; the price target was decreased to $1.50 from $14. PT values the company’s stock at a premium of -142.0 to its Friday closing price.

Price Performance Review of TSHA

On Friday, Taysha Gene Therapies Inc. [NASDAQ:TSHA] saw its stock jump 13.44% to $3.63. On the same session, the stock had its day’s lowest price of $3.1301, but rose to a high of $3.73. Over the last five days, the stock has gained 63.51%. Taysha Gene Therapies Inc. shares have risen nearly 60.62% since the year began. Nevertheless, the stocks have risen 14.87% over the past one year. While a 52-week high of $4.06 was reached on 09/01/23, a 52-week low of $0.50 was recorded on 06/26/23. SMA at 50 days reached $1.20, while 200 days put it at $1.26. A total of 2.99 million shares were traded, compared to the trading of 2.81 million shares in the previous session.

Levels Of Support And Resistance For TSHA Stock

The 24-hour chart illustrates a support level at 3.26, which if violated will result in even more drops to 2.90. On the upside, there is a resistance level at 3.86. A further resistance level may holdings at 4.10. The Relative Strength Index (RSI) on the 14-day chart is 84.20, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.91, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 4.95%. Stochastics %K at 89.92% indicates the stock is a selling.

How much short interest is there in Taysha Gene Therapies Inc.?

A steep rise in short interest was recorded in Taysha Gene Therapies Inc. stocks on Aug 14, 2023, dropping by -0.39 million shares to a total of 0.73 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 1.12 million shares. There was a decline of -52.49%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.74% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.08.

Taysha Gene Therapies Inc. [TSHA] – Who Are The Largest Shareholders?

In filings from RA Capital Management LP, it is revealed that the company now owns 18,472,503 shares, or roughly 28.66% of the outstanding TSHA shares. Additionally, The Vanguard Group, Inc. increased 0.37% of its stake after which the total value it holdings stand at $1,064,061. At present, Laurion Capital Management LP is holding 1,171,832 shares valued at $0.79 million. Fidelity Management & Research Co owned 1,148,827 shares of the company at the time of its most recent 13F filing, worth $0.77 million.

According to FactSet, Taysha Gene Therapies Inc.’s share price will average $5.72 in the next year, based on opinions of analysts polled by the firm. This is up nearly 87.5 percent from its previous closing price of $3.20. Analysts expect Taysha Gene Therapies Inc. stock to reach the higher price of $8.00, while the lowest price estimate is $2.00. However, 9 analysts have rated TSHA stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here